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Abstract
Background: Higher mammographic breast density (MBD) is associated with an increased risk of breast cancer when
compared with lower MBD, especially in premenopausal women. However, little is known about the effectiveness of
chemoprevention agents in reducing MBD in premenopausal women without a history of breast cancer. Findings from this
review should provide insight on how to target MBD in breast cancer prevention in premenopausal women with dense
breasts. Methods: We searched 9 electronic databases for clinical trials in English, Spanish, French, or German published
until January 2020. Articles evaluating the association of pharmacological agents and MBD were included. Data were
extracted on methods, type and dose of intervention, outcomes, side effects, and follow up. Quality of the studies was
assessed using the US Preventive Services Task Force criteria. Results: We identified 7 clinical trials evaluating the
associations of 6 chemoprevention agents with changes in MBD in premenopausal women without history of breast cancer.
The studies evaluated selective estrogen-receptor modulators (n¼1); gonadotropin-releasing hormone agonists (n¼2); isofla-
vones (n¼1); vitamin D (n¼1); and Boswellia, betaine, and mayo-inositol compound (n¼1). Hormonal interventions were as-
sociated with net reductions in percent density (tamoxifen [13.4%], leuprolide acetate [8.9%], and goserelin [2.7%]), whereas
nonhormonal (vitamin D and isoflavone) interventions were not. However, MBD returned to preintervention baseline levels
after cessation of gonadotropin-releasing hormone agonists. Conclusions: A limited number of chemoprevention agents
have been shown to reduce MBD in premenopausal women. Identification of new and well-tolerated chemoprevention
agents targeting MBD and larger studies to confirm agents that have been studied in small trials are urgent priorities for pri-
mary breast cancer prevention in premenopausal women with dense breasts.
In the United States, the incidence of breast cancer in younger
women is increasing (1). About 15% of breast cancer cases are
diagnosed in women younger than 40 years, and they tend to be
larger, more aggressive, and with worse prognosis than in older
women (1-4). Therefore, identifying intermediate and modifi-
able endpoints in breast carcinogenesis is critical for breast can-
cer prevention. However, interventions to reduce breast cancer
risks have been predominantly studied among older women.
Mammographic breast density (MBD), which reflects the
amount of epithelial and stromal tissues in relation to adipose
tissue in the breast, is a strong but modifiable risk factor for
breast cancer (5-7). Women with high MBD (>75%) have a 5-fold
increased risk of breast cancer than women with little or no
dense breast tissue (8,9). This is relevant for premenopausal
women because up to 39% of breast cancer cases are attribut-
able to having dense breasts in this group (10-14). Studies have
shown that a decrease in MBD (10%) in high-risk women is as-
sociated with lower breast cancer risk (63%) (15-17). Hence, MBD
could serve as a surrogate marker of breast cancer development
(13-16) and as a measurable endpoint of treatment response for
preventive interventions (18,19), although it is worth noting
that breast cancer arises from other biological pathways unre-
lated to, and completely independent of, MBD.
Although some pharmacological agents have been evaluated
as potential breast cancer chemoprevention agents (20), only a
few studies have investigated the associations of these agents
with changes in MBD in premnopausal women. Therefore, the
aim of this review is to summarize data from clinical trials that
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have investigated the impact of chemoprevention agents on
MBD in premenopausal women without a history of breast can-
cer. Study findings will provide evidence-based information to
physicians managing premenopausal women with dense




We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses guidelines for conducting and
reporting systematic reviews (21). An experienced medical li-
brarian (LS) searched Ovid Medline, Embase, Scopus, Cochrane
Database of Systematic Reviews, Cochrane Central Register of
Controlled Trials, Health Technology Assessment Database,
NHS Economic Evaluation Database, Clinicaltrials.gov, and
World Health Organization International Clinical Trials Registry
Platform for literature on MBD in premenopausal women pub-
lished through January 22, 2020. An example of the search strat-
egy can be found in the Supplementary Table 1 (available
online). We also reviewed the reference lists of all included
studies for additional publications.
Study Selection
Two reviewers (AS and MR) independently screened the titles
and abstracts of interventional studies in English, Spanish,
French, and German and selected eligible studies for subse-
quent full-text review. Studies were selected based on the popu-
lation, intervention, criteria, outcome criteria, which can be
found in Table 1. Studies including mixed populations of pre-
and postmenopausal women were also included, as long as the
effect of the intervention on MBD among premenopausal
women could be extracted from the study.
Interventional, as opposed to observational, studies allow
for the evaluation of the direct impact of the intervention on
the outcome. We excluded observational studies and confer-
ence abstracts, studies that did not report outcomes by meno-
pausal status, and studies in which the intervention agents
were multivitamins. We also excluded studies without a com-
parison group (22). Disagreements were resolved by discussion.
The inclusion and exclusion criteria can be found in the
Supplementary Table 2 (available online).
Data Extraction and Quality Assessment
Two reviewers (AS and MR) extracted details on study title,
year, design, experimental years, eligibility criteria, population
characteristics (age, race, and menopause status), type and dose
of chemoprevention agents, the associations between the
agents and the outcome of interest, side effects, and duration of
follow-up.
The quality of the studies was assessed based on the US
Preventive Services Task Force (USPSTF) (23) criteria for the as-
sessment of internal validity in clinical trials (Supplementary
Methods, available online). A study was considered “good” if it
met all criteria, “fair” if it did not seem to meet at least 1 crite-
rion but had no “major flaws,” and “poor” if it had at least 1
major flaw (Supplementary Table 3, available online).
Results
Study Selection
Database searches were executed on July 17, 2019, and again on
January 22, 2020, resulting in a total of 3485 citations, which
were identified and exported to Endnote. After the removal of
1958 duplicate records using a standard deduplication process
(24), 1527 unique citations were left for the title and abstract
screening. All articles were in English. Of the 34 articles that
underwent full article review, 7 met the inclusion criteria
(Figure 1). Review of the reference lists of selected studies gener-
ated no additional results. Because of the heterogeneity of the
studies and the limited data for each chemoprevention agent,
we performed a systematic review rather than a meta-analysis.
Study Characteristics and Quality of the Evidence
Seven studies met the inclusion criteria: 5 randomized placebo-
controlled trials (15,25-28) and 2 randomized no-drug controlled
trials (Table 2) (29,30). The majority of the studies were per-
formed in the late 1990s and early 2000s and took place in
Canada (26), Italy (27), the United Kingdom (15,28,30), and the
United States (25,29).
The study populations ranged from 19 to 400 women in their
late 30s and early 40s (Table 3). Most women were non-Hispanic
White. The mean body mass index (BMI) of women enrolled in
the trials was less than 25 kg/m2. Three studies included women
at increased risk for breast cancer (15,27,29), defined by any of
the following criteria: 1) history of ductal carcinoma in situ, lob-
ular carcinoma in situ, and atypical hyperplasia; 2) a predicted
probability of invasive breast cancer of more than 1.7% based on
the Gail model; and 3) known deleterious BRCA1/2 mutation car-
rier or a family history of hereditary breast. Only 2 studies set a
predetermined baseline MBD for study enrollment (15,26). Four
studies limited their study population to premenopausal
women who were not at increased risk for breast cancer (25-
27,29).
No studies were eliminated based on the quality assessment
of bias with majority of studies falling into either the good or
poor category: 3 as good (25,26,30), 2 as fair (15,28), and 2 as poor
(27,29). The most common reasons for marking down a study
Table 1. Description of the PICO strategya
PICO criteria Description
Population Premenopausal women without a history of invasive
breast cancer. We deferred to the author’s defini-
tion of premenopausal status.
Studies including both pre-and postmenopausal
women were also included, as long as the effect of
the intervention on MBD among premenopausal
women could be extracted from the study.
Studies that included women with history of noninva-
sive lesions, such as DCIS, LCIS, or AH were also
considered.
Intervention Any pharmacological agent hypothesized to reduce
MBD, reported by dose and duration of intervention.
Comparison Any.
Outcome Change in MBD reported as extractable data.
aAH ¼ atypical hyperplasia; DCIS ¼ ductal carcinoma in situ; LCIS ¼ lobular car-
cinoma in situ; MBD ¼mammographic breast density; PICO ¼ population, inter-
vention, criteria, outcome.
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3,485 citations identified through 
database searching in July 2019 and 
January 2020 
   1,958 duplicates removed 
1,527 citations screened for titles 
and abstracts 
7 articles included in the 
qualitative analysis 
34 full-text articles for review 
1,493 citations excluded at 






















27 citations removed 
  6 Non-interventional 
  4 Dietary intake 
  5 History of breast cancer  
  2 Multivitamins  
  3 Results not available for premenopausal 
women 
  3 Studies without a comparison group  
  2 Full text not available  
  2 Results already reported in different article  
Figure 1. Flow diagram for included studies by preferred reporting items for systematic review and meta-analyses
Table 2. Characteristics of clinical trials on the associations of chemoprevention agents with mammographic breast density in premenopausal
women and quality assessmenta

























Pasta et al., 2015 (27) Italy 2014-2015 Boswellia, betaine,
and myo-inositol
compound
PO QD 200 mg 6 0 Poor
Powles et al., 2008 (28) UK 2000s Isoflavone PO QD 40 mg 36 0 Fair
Cuzick et al., 2004 (15) UK 1992-2001 Tamoxifen PO QD 20 mg 54 0 Fair




Howell et al., 2018 (30) UK 2000-2004 Goserelin
(þ raloxifene)
SQ Q28D 3.6 mg 24 84 Good





IM Q28D 7.5 mg 12, 24 0-12 Poor
aIU ¼ international unit; IM ¼ intramuscular; PO ¼ per os/oral; QD ¼ every day; Q28D ¼ every 28 days; SQ ¼ subcutaneous; USPSTF ¼ United States Preventive Service
Task Force.
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were failure to perform intention-to treat analysis and limiting
the experimental group to only participants who were
completely adherent to the intervention (Table 2).
Effects of Chemoprevention Agents on Mammographic
Breast Density
Selective Estrogen Receptor Modulators (SERM)
One randomized placebo-controlled trial investigated the
effects of a SERM (tamoxifen [20 mg/day]) on MBD (15).
Compared with placebo, the net reduction in percent density in
the tamoxifen arm was 13.4% (95% confidence interval [CI] ¼
8.6% to 18.1%) after 54 months of treatment in women aged 45
years or younger at trial entry (n¼ 191 women), whereas in
women aged 55 years or older, tamoxifen use was not associ-
ated with reduction in percent density (Table 4). The reduction
in percent density was noticeable as early as the 18th month of
intervention. The study controlled for important confounders,
including BMI, age at entry to the trial, menopausal status, pre-
dicted familial risk of breast cancer, previous breast biopsy, and
smoking status (31).
Gonadotropin-Releasing Hormone Agonists (GnRHA)
The 2 GnRHAs (leuprolide acetate and goserelin) were associ-
ated with net reductions in percent density in women at a high
risk for developing breast cancer compared with placebo.
Treatment with leuprolide acetate (n¼ 19 women) was associ-
ated with an 8.9% reduction in percent density (29), whereas
treatment with goserelin (30) (n¼ 47 women) was associated
with a 2.7% reduction in percent density (Table 4). The
interventions took place over 24 months in both studies. None
of the studies adjusted their analyses for BMI or age.
Isoflavone
Isoflavone use was not associated with a reduction in MBD in
the 2 studies that investigated this (25,28). There were non-
statistically significant increases in the mean percent density in
the isoflavone arm (2.5%) compared with the placebo arm (0.4%)
after 12 months of intervention (100 mg/day of isoflavone vs pla-
cebo) (25). In the second study, the mean reduction in MBD in
the isoflavone arm (40 mg/day) was lower (-3.0%) compared
with the placebo arm (-6.6%, P ¼ .2) after 36 months of interven-
tion (28) (Table 4). Both studies used digitized mammograms.
Boswellia, Betaine, and Myo-Inositol (Eumastos)
Treatment with Eumastos, which combined boswellia, betaine,
and myo-inositol, was associated with a 60% reduction in MBD
after 6 months of treatment (P < .01) compared with a non-
statistically significant 9.1% reduction (net difference of 50.9%)
in MBD among women assigned to placebo (27). The analysis
was not controlled for BMI or age.
Vitamin D
Vitamin D at 1000, 2000, and 3000 IU/day for 12 months did not
reduce MBD when compared with placebo (26) (Table 4).
Vitamin D at a dose of 3000 IU/day resulted in a slowing of the
natural decrease in MBD compared with that observed in the
placebo group: mean difference -1.9 (95% CI ¼ -3.7 to -0.1; P
¼ .03). Dose response analyses showed a decrease in the rate of
annual percent density change with an increasing dose of
Table 3. Baseline characteristics of premenopausal women enrolled into the clinical trialsa
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No
36 (NA) NA NA













aBMI ¼ body mass index; IU ¼ international unit; NA ¼ not available
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vitamin D (P ¼ .02). Analysis was controlled for age, BMI, cal-
cium intake, initial percent breast density, timing, and technol-
ogy of mammography.
Persistent Reduction in MBD After Cessation of
Intervention
Of the 4 chemoprevention agents that resulted in MBD reduc-
tion, only 2 (leuprolide acetate and goserelin) had posttreatment
follow-up. Gram et al. (29) showed that MBD after 6-12 months
off leuprolide acetate was not statistically significantly different
from baseline. Similarly, Howell et al. (30) showed that after ces-
sation of goserelin treatment, MBD tended to return to pretreat-
ment baseline. Persistence of the effect of tamoxifen and
Eumastos was not reported.
Methods for Assessing Mammographic Breast Density
Methods used to assess MBD ranged from Boyd classification
(15,27,30), visual assessment scores (28,30), and computer-
assisted methods (Table 4) (25,26,29). Some studies used digital
mammography for assessing MBD (26,28), whereas others
scanned views of the mammogram and digitalized them
(15,25,28,29). One study did not specify the type of mammogram
used (27). For most studies, images were deidentified, order of
films were randomized, and the intervention groups were
blinded to reviewers to reduce bias (Table 4).
Discussion
In this systematic review, we identified 7 clinical trials that in-
vestigated the associations of 6 chemoprevention agents with
changes in MBD in premenopausal women with no history of
breast cancer. To the best of our knowledge, this is the first sys-
tematic review on this subject. Only hormonal interventions
(tamoxifen and GnRHAs) were associated with a reduction in
MBD, and only tamoxifen was associated with a clinically rele-
vant net reduction (>10%) in MBD after more than 12 months of
treatment. However, MBD appeared to return to baseline levels
after cessation of GnRHAs, and there is limited data on the
long-term effect of tamoxifen for chemoprevention.
Hormonal interventions that modulate estrogen exposure
influence breast cancer incidence in a direction predictable by
their impact on estrogen levels (32,33). GnRHAs suppress the
ovarian production of breast cell mitogens such as estrogen and
decrease premenopausal breast epithelial cell proliferation
(34,35). Interestingly, Howell et al. (30) used goserelin in con-
junction with a SERM (ie, raloxifene). The latter ingredient was
used as a supporting agent to mitigate adverse events (ie, pre-
serve bone density) rather than an active ingredient for MBD re-
duction. Raloxifene is not indicated for use in premenopausal
women because it has not shown a reduction in MBD when
used on its own in this population (36). On the other hand,
SERMs such as tamoxifen bind to a and b estrogen receptors to
activate estrogenic or antiestrogenic activities depending on the
tissue (37,38). However, although most SERMs share a similar
mechanism of action, only tamoxifen, as opposed to raloxifene
or acolbifene (36,39), has shown a reduction in MBD. It is possi-
ble that this activity is due to a noncanonical pathway specific
to tamoxifen, such as its pro-apoptotic activity through inhibi-
tion of cancerous inhibitor of protein phosphatase 2A and
phospho-Akt (40,41). Thus, a better understanding of underlying
mechanisms by which tamoxifen reduces MBD is needed.
Eumastos (boswellia, betaine, and myo-inositol) may act
synergistically to exert numerous critical activities that could
explain its effect on MBD. Myo-inositol reduces the expression
of tumor growth factor-b and nuclear factor–kB and controls in-
flammation in breast cancer cells (42,43). Boswellia modulates
the expression of signaling molecules and cell-cycle regulators
such as caspases, cytokines, and cyclin D1 (44). Betaine plays a
role in breast cancer development and epigenetics specifically,
serving as a methyl donor for conversion of homocysteine to
methionine (45). Although Eumastos appears to be associated
with a reduction in MBD after 6 months of treatment, there
were several notable weaknesses in the study design, which
limit how study findings can be interpreted. Thus, appropriately
designed larger studies with robust adjustment for confounders
and clearly defined density measures are needed to confirm the
findings in the study. Finally, despite the initial promise of both
vitamin D and isoflavones as chemoprevention agents from ob-
servational and experimental studies (46-50), up-to-date meta-
analyses have shown no reduction in MBD with vitamin D
(51,52) or isoflavones (53).
The effect of tamoxifen in premenopausal women is consis-
tent with findings in postmenopausal women (36), and the
USPSTF guidelines recommend its use as a chemoprevention
agent in select populations (USPSTF) (20,54). The International
Breast Cancer Intervention Study (IBIS) demonstrated that com-
pared with women in the placebo group, women in the tamoxi-
fen group who experienced at least 10% reduction in MBD had a
63% reduction in breast cancer risk while women who took ta-
moxifen but experienced less than 10% reduction in MBD did
not have a reduction in breast cancer risk (55). A plausible expla-
nation is that some women do not efficiently metabolize ta-
moxifen and will fail to demonstrate a treatment benefit,
possibly due to genetic predisposition (56-58). Thus, for women
receiving tamoxifen, assessing for MBD changes throughout the
intervention period could determine who will benefit from ta-
moxifen and those who should receive alternative interventions
(59). Furthermore, longer posttreatment cessation follow-up pe-
riod is needed to evaluate the sustainability of the effect on
MBD and evaluate a reduction in breast cancer incidence.
Although MBD could serve as a surrogate marker of breast
cancer development (13-16), it is also worth noting that breast
cancer can arise from other biological pathways unrelated to,
and completely independent of, MBD. Hence, the fact that a
chemoprevention agent does not reduce MBD does not imply
that it has no utility in breast cancer prevention. In addition to
assessing a change in MBD as an intermediate response end-
point, chemoprevention studies should evaluate the effect of
other chemoprevention agents on other biomarkers that may
be predictive of breast cancer incidence.
Despite tamoxifen being approved as breast chemopreven-
tion by the Food and Drug Administration, its uptake for pri-
mary prevention in the United States is less than 3%, because of
its side effects (60-63). Toxicity of the intervention can limit the
acceptability and adherence to treatment. Adverse events were
reported in 4 studies, although only 3 actively and systemati-
cally monitored for them. Although some studies did not assess
for side effects of the interventions such as tamoxifen and leu-
prolide acetate, its use in other studies has been associated
with vasomotor symptoms, menstrual abnormalities, uterine
cancer, and thromboembolic phenomena (64,65). Goserelin was
associated with vasomotor symptoms and sexual dysfunction,
as well as weight gain and headaches (29). Up to 40% of the par-
ticipants in the intervention arm indicated that they would not
consider the option of further treatment for 5 years because of
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the side effects, whereas several women opted out of the study
because of treatment toxicity. As such, identification of new
and well-tolerated chemoprevention agents targeting MBD is an
urgent priority for primary breast cancer prevention.
A number of important limitations were found in the studies
reviewed. Only 2 of the trials adjusted for important confounders
such as BMI and age, which are both important determinants of
MBD. Identified lifestyle factors account for 33% of the variance
in MBD with current BMI accounting for the majority of this vari-
ance (66); hence, not adjusting for BMI is a major weakness
when evaluating a chemoprevention agent. Methods for measur-
ing MBD varied across studies with many of them utilizing Boyd
classification and other computer-assisted measurements after
digitalizing mammograms for MBD assessment. Currently, digi-
tal mammography is widely used, and new software packages
are available for reporting MBD. Only 2 studies set a predeter-
mined baseline MBD for study enrollment. Future studies should
consider limiting trial enrollment to women with heteroge-
neously dense and extremely dense breasts because these are
the groups with an elevated risk of breast cancer. Thus, there is
an opportunity for future studies evaluating changes in MBD in
response to chemoprevention agents to provide greater granular
insight by using newer area- and volumetric-based measures,
which provide more robust quantitative measures.
Studies did not always specify at which point within the
menstrual cycle mammograms were taken, which is important
because MBD varies with hormonal changes of the menstrual
cycle (67). There was a lack of an adequate posttreatment
follow-up, which is important for both determining the persis-
tence of MBD reducing effect and long-term side effect profile.
There was a lack of racial diversity in the study population,
which limits generalizability of the results. Most of the studies
included mostly non-Hispanic White women. This is relevant
because MBD varies by race and ethnicity.Asian and African
American women are more likely to have higher MBD, whereas
Hispanic and Native American women have similar MBD com-
pared with non-Hispanic White women (66,68-71). Furthermore,
racial differences in response to some of the agents, such as the
reduced breast cancer risk associated with isoflavone intake in
Asian ethnicity vs non-Asian ethnicity women, have been pre-
viously demonstrated (47,48). Hence, studies among African
American and Asian women are needed.
A potential limitation of this review is that we might have
missed relevant articles. However, with our extensive literature
search, we believe that all relevant publications are included in
this review. An important strength of this review is that it is the
first systematic review to evaluate data from clinical trials on
the effect of chemoprevention agents on mammographic breast
density in premenopausal women. This is especially timely
given the recent USPSTF recommendations on chemopreven-
tion use in high-risk women (54) and updated results on the
IBIS-II trial in postmenopausal women (72). As such, findings
could generate new ideas on breast cancer prevention in preme-
nopausal women. Furthermore, we followed well-established
guidelines on study selection.
In summary, only a limited number of chemoprevention
agents have been shown to reduce MBD in premenopausal
women without a history of invasive breast cancer. New and
well-designed randomized controlled trials targeting new che-
mopreventive agents with robust MBD assessments and longer
posttreatment follow-ups, as well as larger studies to confirm
agents that have been studied in small trials, are needed to
identify well-tolerated chemoprevention agents that can reduce
MBD with minimal side effects. This has great potentials to
open up new opportunities for breast cancer prevention in pre-
menopausal women.
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